Nongfu Shop Digital New Retail Co., Ltd — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nongfu Shop Digital New Retail Co., Ltd filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | May 22, 2025 |
| FY2024 | Dec 31, 2023 | $0 | May 22, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $0 | May 21, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($39.8K) | May 22, 2025 |
| FY2024 | Dec 31, 2023 | ($62.0K) | May 22, 2025 |
| FY2023 | Dec 31, 2022 | ($96.2K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($750.9K) | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | $288.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($84.2K) | May 21, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($39.8K) | May 22, 2025 |
| FY2024 | Dec 31, 2023 | ($62.0K) | May 22, 2025 |
| FY2023 | Dec 31, 2022 | ($82.0K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($779.0K) | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | ($25.8K) | Mar 31, 2022 |
| FY2011 | Dec 31, 2011 | ($170.5K) | Apr 25, 2012 |
| FY2011 | Dec 31, 2010 | ($183.1K) | Apr 25, 2012 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $2.6K | Apr 25, 2012 |
| FY2011 | Dec 31, 2010 | $3.9K | Apr 25, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | May 22, 2025 |
| FY2024 | Dec 31, 2023 | $0 | May 22, 2025 |
| FY2023 | Dec 31, 2022 | ($53.6K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | ($25.8K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($20.3K) | May 21, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | May 22, 2025 |
| FY2024 | Dec 31, 2023 | $0 | May 22, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $0 | May 21, 2021 |
| FY2011 | Dec 31, 2011 | $69.7K | Apr 25, 2012 |
| FY2011 | Dec 31, 2010 | $82.1K | Apr 25, 2012 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $106.7K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $44.6K | Apr 15, 2024 |
| FY2020 | Dec 31, 2020 | $580.5K | May 21, 2021 |
| FY2020 | Dec 31, 2019 | $1.34M | May 21, 2021 |
| FY2011 | Dec 31, 2011 | $705.3K | Apr 25, 2012 |
| FY2011 | Dec 31, 2010 | $483.1K | Apr 25, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($146.5K) | May 22, 2025 |
| FY2024 | Dec 31, 2023 | ($106.7K) | May 22, 2025 |
| FY2024 | Dec 31, 2022 | ($44.6K) | May 22, 2025 |
| FY2023 | Dec 31, 2021 | ($518.5K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | ($580.5K) | Apr 21, 2023 |
| FY2021 | Dec 31, 2019 | ($1.34M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($1.28M) | May 21, 2021 |
| FY2011 | Dec 31, 2011 | ($635.6K) | Apr 25, 2012 |
| FY2011 | Dec 31, 2010 | ($401.0K) | Apr 25, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.72M) | May 22, 2025 |
| FY2024 | Dec 31, 2023 | ($3.68M) | May 22, 2025 |
| FY2023 | Dec 31, 2022 | ($3.61M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($3.52M) | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | ($2.77M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.06M) | May 21, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | May 21, 2021 |
| FY2020 | Dec 31, 2019 | $0 | May 21, 2021 |
| FY2020 | Dec 31, 2018 | $0 | May 21, 2021 |
| FY2011 | Dec 31, 2011 | $30.5K | Apr 25, 2012 |
| FY2011 | Dec 31, 2010 | $39.4K | Apr 25, 2012 |
| FY2011 | Dec 31, 2009 | $117.5K | Apr 25, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Apr 21, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | May 21, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | May 22, 2025 |
| FY2024 | Dec 31, 2023 | 0 | May 22, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Apr 21, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 189.12M | May 22, 2025 |
| FY2024 | Dec 31, 2023 | 189.12M | May 22, 2025 |
| FY2023 | Dec 31, 2022 | 189.12M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 135.57M | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | 105.57M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 105.57M | May 21, 2021 |